Angiotech partner to release broad range of clinical trial results on market-leading TAXUS(R) EXPRESS2(TM) coronary stent system
20 Mai 2005 - 5:13PM
PR Newswire (US)
Angiotech partner to release broad range of clinical trial results
on market-leading TAXUS(R) EXPRESS2(TM) coronary stent system and
next-generation TAXUS(R) Liberte(TM) system at Paris Course on
Revascularization ARRIVE and other registry data also to be
released VANCOUVER, May 20 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) corporate
partner, Boston Scientific ("BSC"), today announced the schedule of
BSC's major events and press announcements at the Paris Course on
Revascularization (EuroPCR), which runs from May 24 to 27 in Paris.
"The data we will present at PCR is part of a continuum of
consistent, durable results over a broad range of time, trials,
lesions and patients," said Paul LaViolette, Chief Operating
Officer of Boston Scientific. "We expect this data will further
solidify and justify our leadership in drug-eluting stents. We will
present long-term data on our current drug-eluting stent platform,
as well as first-time data on our next-generation product, TAXUS
Liberte." Tuesday, May 24 (all times are Paris time)
------------------------------------------ - TAXUS V IVUS Results.
At 5:30 p.m., BSC will release nine-month intravascular ultrasound
(IVUS) follow-up results from its TAXUS V clinical trial, which
assesses the safety and efficacy of its TAXUS(R) Express2(TM)
paclitaxel-eluting stent system. TAXUS V expands on the TAXUS IV
pivotal trial and studies the most challenging lesions and
highest-risk patients ever studied in a randomized, controlled
clinical trial in the United States. The results will be presented
by Neil Weissmann, M.D., at a session entitled "Deep Insight into
Long Lesions" in Room 1 of the Palais des Congres, 2 Place de la
Porte Maillot, Paris. BSC will also issue a press release at that
time. - TAXUS VI Results. At 5:40 p.m., BSC will release two-year
results from its TAXUS VI clinical trial, which evaluates the
safety and efficacy of a moderate-release formulation of its TAXUS
Express2 paclitaxel- eluting stent in high-risk patients, including
long lesions, small vessels and diabetics. (BSC's current
commercialized product uses a slow-release formulation.) The
results will be presented by Eberhard Grube, M.D., the study's
Co-Principal Investigator, in Room 1. BSC will also issue a press
release at that time. Wednesday, May 25 ----------------- -
Symposium on Future of DES. At 12:00 p.m., BSC will host a
symposium entitled "Toward New Frontiers: Using Data to Drive the
Future" chaired by Keith Dawkins, M.D., in Room 1. ATLAS results.
During the symposium, Mark Turco, M.D., is scheduled to present
30-day results from BSC's ATLAS clinical trial, a pivotal study
designed to support U.S. Food and Drug Administration approval of
TAXUS(R) Liberte(TM), BSC's next-generation, paclitaxel-eluting
stent system. BSC will issue a press release at that time on the
ATLAS 30-day results release. TAXUS V diabetic results. The
symposium will also include a presentation by Gregg W. Stone, M.D.,
on nine-month diabetic sub- population data from the TAXUS V
clinical trial. BSC will also issue a press release at that time on
TAXUS V nine-month diabetic sub- population data. SYNTAX, TAXUS
moderate release. Marie-Claude Morice, M.D., will also present an
update on enrollment in BSC's SYNTAX clinical trial, a randomized
comparison of the TAXUS stent system with cardiac surgery in
complex patients. Mary E. Russell, M.D., Boston Scientific Senior
Vice President, Clinical and Regulatory, and Chief Medical Officer,
will address the issue of whether there is a future clinical role
for the TAXUS moderate-release formulation. - Analyst Meeting. At
2:00 p.m., BSC will host an analyst meeting in the Salon Derain of
Le Meridien Etoile Hotel, located directly across from the Palais
des Congres, at 81 Boulevard Gouvion Saint-Cyr. The meeting is open
to the media. BSC will issue a press release at the time of the
meeting. This meeting is being webcast and can be accessed at
Boston Scientific's website, http://www.bostonscientific.com/.
Please visit the website beginning May 18 for details on how to
access the webcast. To ensure a timely connection to the webcast it
is recommended that users register at least 15 minutes before the
webcast begins. A replay of the webcast will be archived and
available for 10 business days in the Webcast and Archives section
of the Investor Relations site at http://www.bostonscientific.com/
beginning at approximately 12:00 p.m. EST on May 25 and running
through June 6. - ARRIVE and MILESTONE II Registries. At 5:30 p.m.,
BSC will release results from its ARRIVE and MILESTONE II
post-market registries, during a symposium entitled "Post-Market
Registries: A Wealth of Real Life Data", chaired by Mary E.
Russell, M.D. The symposium will take place in Room 4 and will
examine real-world outcomes from a combined population of nearly
8,000 patients worldwide. Specific registry data will be presented
by John Lasala, M.D., Ph.D., Kari Niemela, M.D., and H. Stoerger,
M.D. BSC will also issue a press release at that time. Thursday,
May 26 ---------------- - OLYMPIC Registry Enrollment Update. On
Thursday, BSC will issue a press release updating enrollment status
for the TAXUS OLYMPIC registry. The world's largest drug-eluting
stent registry plans to enroll more than 30,000 patients at more
than 600 centers in the United States, Europe and other
international locations. The registry is designed to collect and
analyze "real-world" clinical outcomes data for BSC's
next-generation TAXUS Liberte paclitaxel-eluting stent system.
Friday, May 27 -------------- - DES Plenary Session. From 12:00 -
2:30 p.m., Mary E. Russell, M.D., will participate in a plenary
session entitled, "Direct Comparison between DES: A Burning Issue"
chaired by Jean Marco, M.D., in Room 1. BSC acquired worldwide
exclusive rights from Angiotech to use paclitaxel to coat its
coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. Vancouver-based Angiotech
Pharmaceuticals, Inc. is a specialty pharmaceutical company
pioneering the combination of pharmaceutical compounds with medical
devices and biomaterials to both create novel solutions for poorly
addressed disease states and dramatically improve surgical
outcomes. To find out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," "may" and "will" and words of
similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. CONTACTS: Todd Young, Angiotech
Pharmaceuticals (Analysts & Investors) (604) 221-7676 ext 6933
Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts) (604)
221-7676 ext 6996 Eric Starkman, Starkman & Associates (Media)
(212) 252-8545 ext 12 DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Todd Young, Angiotech Pharmaceuticals (Analysts &
Investors) (604) 221-7676 ext 6933; Rui Avelar, Angiotech
Pharmaceuticals, Inc. (Analysts) (604) 221-7676 ext 6996; Eric
Starkman, Starkman & Associates (Media) (212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024